To evaluate the clinical efficacy and safety of recombinant mussel adhesive protein dressing imported by Shumin star in the treatment of facial hormone-dependent dermatitis. Methods A total of 67 patients with facial hormone-dependent dermatitis admitted to the Yantai Academy of Agricultural Sciences Chinese Medicine Dermatology Hospital from March 2022 to March 2023 were selected and divided into control group (n =33) and observation group (n =34) according to the random number table method. The control group was treated with conventional drugs, and the observation group was treated with recombinant mussel adhesive protein dressing imported by Shumin star on the basis of the control group. The clinical symptom score, pruritus score, clinical efficacy and quality of life were compared between the two groups before and after treatment. The patients were followed up for 3 months to observe the recurrence of the two groups. Results After treatment, the skin lesion area score, erythema score and desquamation score of the two groups were better than those before treatment, and those in the observation group was better than those in the control group (P <0.05). The pruritus score of the two groups after treatment was better than that before treatment, and that in the observation group was better than that in the control group (P <0.05). The total effective rate of treatment in the observation group was 94.12%, which was higher than 75.76% in the control group (P <0.05). The scores of quality of life in the observation group were higher than those in the control group (P <0.05). The recurrence rate of the observation group was 8.82%, which was lower than 36.36% of the control group (P <0.05). Conclusion Recombinant mussel adhesive protein dressing imported by Shumin star can effectively improve the symptoms of facial hormone-dependent dermatitis and repair the damaged skin barrier. It has the characteristics of good clinical efficacy and high safety, and is worthy of clinical application.